New combo aims to control myeloma relapse after transplant
NCT ID NCT03413800
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This study tested a two-step treatment for multiple myeloma that came back after a stem cell transplant. First, patients received lenalidomide and dexamethasone to reduce the cancer and prepare the immune system. Then, they received infusions of immune cells from their original donor to boost the anti-cancer effect. The goal was to improve disease control and delay progression, but this is not a cure as ongoing management is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CIUSSS de l'Est-de-l'île-de-Montréal, Installation Hôpital Maisonneuve Rosemond
Montreal, Quebec, H1T2M4, Canada
Conditions
Explore the condition pages connected to this study.